About US
Contact us
-
AstraZeneca rounds out stellar China year—and beats Roche to the punch—with Imfinzi lung cancer nodAstraZeneca’s oncology business has chalked up several wins in China this year. Now, the British drugmaker has another important one to brag about. China’s National Medical Products Administrationapp2019/12/16
-
ESMO I-O: Keytruda shines among KRAS-mutated patients in Merck's latest lung cancer analysisGENEVA—With all the buzz about KRAS these days, Merck’s been fielding its fair share of questions about whether lung cancer patients with KRAS mutations respond as well to Keytruda as other previousl2019/12/13
-
SABCS: Merck's Keytruda notches win in triple-negative breast cancer as Roche's Tecentriq falls shortSAN ANTONIO—Merck & Co.'s Keytruda and Roche's Tecentriq are battlingfor immuno-oncology supremacy in an ever-growing range of indications. But in hard-to-treat triple-negative breast cancer (TNB2019/12/13
-
Bayer's $7.6B bid to offload animal health to Elanco draws extra FTC antitrust attentionBayer’s eager to send its animal health unit toElancoso it can focus its healthcare efforts on pharmaceuticals. But that $7.6 billion selloff, like many other recent life sciences deals, has hit an a2019/12/12
-
How will Sanofi save €2B? Chopping support staff and 'smart' purchasing, for 2Like many a corporate rejuvenation plan, CEO Paul Hudson's blueprint for Sanofi includes some hefty cost cutting. The French drugmaker's aiming for €2 billion in annual savings by 2022, executives sa2019/12/12
-
Sanofi, Regeneron uncouple on long-standing drug partnership, splitting up Praluent, KevzaraAfter more than a decade of working together, Sanofi and Regeneron's drug partnership finally turned a profit recentlyon the back of strong sales of blockbuster Dupixent. Instead of staying the cours2019/12/11
-
J&J CEO promises talc is asbestos-free, but spurns his chance to tell Congress whyCompanies embroiled in controversies often send top execs to face questions in Congress. That's not the case for Johnson & JohnsonCEO Alex Gorsky, who has spurned "repeated" requests froma House2019/12/11
-
Roche extends Spark deal offer for shorter period. Are antitrust decisions finally near?For the past half a year or so, Roche has repeatedly postponed its tender offer deadline for Spark Therapeutics, typically fora month each time. This time around, the extension only lasts a week. Ins2019/12/10
-
Samsung execs face jail for destroying evidence in Biogen JV fraud probeSamsung BioLogics has fought accusations that it inflated the value of its Biogen biosimilar joint venture Samsung Bioepis, breaking accounting rules in the process. Counter to that defense? The fact2019/12/10
-
ASH: AbbVie, Roche pad their case for fixed-duration Venclexta use in CLLORLANDO, FLORIDA—AbbVie and Roche have been fielding their fair share of questions about how well a fixed-duration regimen of Venclexta and Rituxan cankeep chronic lymphocytic leukemia (CLL) from ret2019/12/9